Nephros Income from Continuous Operations 2010-2025 | NEPH
Nephros income from continuous operations from 2010 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
| Nephros Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $-2 |
| 2022 | $-4 |
| 2021 | $-3 |
| 2020 | $-5 |
| 2019 | $-3 |
| 2018 | $-3 |
| 2017 | $-1 |
| 2016 | $-3 |
| 2015 | $-3 |
| 2014 | $-7 |
| 2013 | $1 |
| 2012 | $-3 |
| 2011 | $-2 |
| 2010 | $-2 |
| 2009 | $-2 |
| Nephros Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2025-06-30 | $0 |
| 2025-03-31 | $1 |
| 2024-12-31 | $0 |
| 2024-09-30 | $0 |
| 2024-06-30 | $0 |
| 2024-03-31 | $0 |
| 2023-12-31 | $-1 |
| 2023-09-30 | $0 |
| 2023-06-30 | $0 |
| 2023-03-31 | $0 |
| 2022-12-31 | $-1 |
| 2022-09-30 | $-1 |
| 2022-06-30 | $-1 |
| 2022-03-31 | $-2 |
| 2021-12-31 | $0 |
| 2021-09-30 | $-1 |
| 2021-06-30 | $-1 |
| 2021-03-31 | $-1 |
| 2020-12-31 | $-1 |
| 2020-09-30 | $-1 |
| 2020-06-30 | $-2 |
| 2020-03-31 | $-1 |
| 2019-12-31 | $0 |
| 2019-09-30 | $-1 |
| 2019-06-30 | $-1 |
| 2019-03-31 | $-1 |
| 2018-12-31 | $-1 |
| 2018-09-30 | $-1 |
| 2018-06-30 | $-1 |
| 2018-03-31 | $-1 |
| 2017-12-31 | $1 |
| 2017-09-30 | $-1 |
| 2017-06-30 | $-1 |
| 2017-03-31 | $-1 |
| 2016-12-31 | $-1 |
| 2016-09-30 | $-1 |
| 2016-06-30 | $-1 |
| 2016-03-31 | $-1 |
| 2015-12-31 | $-1 |
| 2015-09-30 | $-1 |
| 2015-06-30 | $-2 |
| 2015-03-31 | $0 |
| 2014-12-31 | $-1 |
| 2014-09-30 | $3 |
| 2014-06-30 | $-5 |
| 2014-03-31 | $-4 |
| 2013-12-31 | $4 |
| 2013-09-30 | $-1 |
| 2013-06-30 | $-1 |
| 2013-03-31 | $-1 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $-1 |
| 2012-06-30 | $-1 |
| 2012-03-31 | $-1 |
| 2011-12-31 | $-1 |
| 2011-09-30 | $0 |
| 2011-06-30 | $-1 |
| 2011-03-31 | $-1 |
| 2010-12-31 | $-1 |
| 2010-09-30 | $0 |
| 2010-06-30 | $0 |
| 2010-03-31 | $-1 |
| 2009-12-31 | $0 |
| 2009-09-30 | $0 |
| 2009-06-30 | $0 |
| 2009-03-31 | $-1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.042B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $225.007B | 26.38 |
| Boston Scientific (BSX) | United States | $154.324B | 36.80 |
| Stryker (SYK) | United States | $144.711B | 29.46 |
| EssilorLuxottica (ESLOY) | France | $142.399B | 0.00 |
| Medtronic (MDT) | Ireland | $117.900B | 16.72 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.114B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.571B | 24.87 |
| ResMed (RMD) | United States | $41.687B | 29.81 |
| Agilent Technologies (A) | United States | $33.767B | 22.01 |
| GE HealthCare Technologies (GEHC) | United States | $33.630B | 15.81 |
| Terumo (TRUMY) | Japan | $27.538B | 32.63 |
| Koninklijke Philips (PHG) | Netherlands | $26.220B | 17.34 |
| Insulet (PODD) | United States | $22.229B | 74.48 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.230B | 12.88 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.039B | 0.00 |
| Baxter (BAX) | United States | $12.558B | 9.70 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.773B | 28.55 |
| Lantheus Holdings (LNTH) | United States | $3.704B | 10.01 |
| Envista Holdings (NVST) | United States | $3.460B | 24.21 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.179B | 14.10 |
| Perrigo (PRGO) | Ireland | $3.169B | 7.91 |
| ICU Medical (ICUI) | United States | $2.762B | 18.81 |
| Haemonetics (HAE) | United States | $2.521B | 11.25 |
| LeMaitre Vascular (LMAT) | United States | $2.169B | 46.51 |
| Curaleaf Holdings (CURLF) | Canada | $1.969B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.827B | 78.46 |
| QuidelOrtho (QDEL) | United States | $1.762B | 11.09 |
| AtriCure (ATRC) | United States | $1.760B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.299B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.284B | 18.25 |
| Phibro Animal Health (PAHC) | United States | $1.239B | 15.84 |
| BioLife Solutions (BLFS) | United States | $1.213B | 2532.00 |
| Neogen (NEOG) | United States | $1.195B | 18.97 |
| Acuren (TIC) | United States | $1.153B | 0.00 |
| InMode (INMD) | Israel | $0.903B | 8.35 |
| Valneva SE (VALN) | France | $0.891B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.820B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.662B | 0.00 |
| SNDL (SNDL) | Canada | $0.554B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.543B | 0.00 |
| Surmodics (SRDX) | United States | $0.538B | 0.00 |
| ZimVie (ZIMV) | United States | $0.531B | 20.47 |
| Cresco Labs (CRLBF) | United States | $0.489B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.447B | 15.40 |
| CeriBell (CBLL) | United States | $0.432B | 0.00 |
| Owens & Minor (OMI) | United States | $0.417B | 3.70 |
| Evolus (EOLS) | United States | $0.414B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.357B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.356B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.330B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.324B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.304B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.271B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 20.26 |
| Omeros (OMER) | United States | $0.254B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.251B | 0.00 |
| Cerus (CERS) | United States | $0.243B | 0.00 |
| Brainsway (BWAY) | Israel | $0.242B | 49.35 |
| Vireo Growth (VREOF) | United States | $0.240B | 0.00 |
| Quanterix (QTRX) | United States | $0.211B | 0.00 |
| Organigram Global (OGI) | Canada | $0.209B | 0.00 |
| High Tide (HITI) | Canada | $0.207B | 0.00 |
| Exagen (XGN) | United States | $0.206B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.203B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 15.21 |
| FitLife Brands (FTLF) | United States | $0.152B | 18.67 |
| Biote (BTMD) | United States | $0.147B | 4.89 |
| TriSalus Life Sciences (TLSI) | United States | $0.147B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.130B | 0.00 |
| MacroGenics (MGNX) | United States | $0.102B | 0.00 |
| Jin Medical (ZJYL) | China | $0.099B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.14 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.086B | 0.00 |
| Apyx Medical (APYX) | United States | $0.080B | 0.00 |
| Safety Shot (SHOT) | United States | $0.074B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.072B | 0.00 |
| ImmuCell (ICCC) | United States | $0.061B | 35.37 |
| Agape ATP (ATPC) | $0.061B | 0.00 | |
| Veru (VERU) | United States | $0.054B | 0.00 |
| MariMed (MRMD) | United States | $0.051B | 0.00 |
| Zynex (ZYXI) | United States | $0.048B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 14.04 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |